Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review

Maharaj, Ashika; Samoborec, Stella; Evans, Sue; Zalcberg, John; Goldstein, David; Merrett, Neil D.; White, Kate; Croagh, Daniel; Pilgrim, Charles; Evans, Peter; Knowles, Brett; Leong, Trevor; Philip, Jennifer; Smith, M E Beth; Ioannou, Liane

doi:10.1016/j.hpb.2019.09.002

Cited by 29 publications

(31 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is because many patients experience disease progression or death early in the course of therapy due to the highly aggressive disease nature and leave the study. A recent systemic review of patient reported outcomes in pancreatic cancer revealed that questionnaire completion rates fell below 10% of the original cohort within 12 months in patients with unresectable stage (compared to 75% in patients with resectable stage) 24 . For this reason and also because there is no gold standard for handling missing data in variance analysis, we chose the parameter of time to definitive deterioration of GHS/QOL by 5% as the primary end point of the QoL analysis following the methodology described by Awad et al 1 Because a definitive deterioration can often be captured before a patient's deterioration in physical status affects compliance, this methodology is less affected by missing data than the classical repeated measures analysis of variance.…”

Section: Discussionmentioning

confidence: 99%

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

Al‐Batran

Hofheinz

Reichart

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

Few data exist on health‐related quality of life (QoL) in patients with metastatic pancreatic cancer (mPC) receiving first‐line chemotherapy (Awad L ZE, Mesbah M Boston, MA. Applying survival data methodology to analyze quality of life data, in Mesbah M, Cole BF, Ting Lee M‐L (eds): Statistical Methods for Quality of Life Studies: Design, Measurements and Analysis. Kluwer Academic Publishers 2002). The QOLIXANE study is a prospective, noninterventional, multicenter substudy of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer (PARAGON) registry, which evaluated QoL in patients with mPC receiving first‐line gemcitabine and nab‐paclitaxel chemotherapy in real‐life setting. QoL was prospectively measured via EORTC QLQ‐C30 questionnaires at baseline and every month thereafter. Therapy and efficacy parameters were prospectively collected. Main objectives were the rate of patients without deterioration of Global Health Status/QoL (GHS/QoL) at 3 and 6 months. Six hundred patients were enrolled in 95 German study sites. Median progression‐free survival was 5.9 months (95% confidence interval [CI], 5.2‐6.3). Median overall survival (OS) was 8.9 months (95% CI, 7.9‐10.2), while median time to deterioration of GHS/QoL was 4.7 months (95% CI, 4.0‐5.6). With a baseline GHS/QoL score of 46 (SD, 22.8), baseline QoL of the patients was severely impaired, in most cases due to loss in role functioning and fatigue. In the Kaplan‐Meier analysis, 61% and 41% of patients had maintained GHS/QoL after 3 and 6 months, respectively. However, in the QoL response analysis, 35% and 19% of patients had maintained (improved or stable) GHS/QoL after 3 and 6 months, respectively, while 14% and 9% had deteriorated GHS/QoL with the remaining patients being nonevaluable. In the Cox regression analysis, GHS/QoL scores strongly predicted survival with a hazard ratio of 0.86 (P < .0001). Patients with mPC have poor QoL at baseline that deteriorates within a median of 4.7 months. Treatment with gemcitabine and nab‐paclitaxel is associated with maintained QoL in relevant proportions of patients. However, overall, results remain poor, reflecting the aggressive nature of the disease.

show abstract

Section: Discussionmentioning

confidence: 99%

Quality of life and outcome of patients with metastatic pancreatic cancer receiving first‐line chemotherapy with nab‐paclitaxel and gemcitabine: Real‐life results from the prospective QOLIXANE trial of the Platform for Outcome, Quality of Life and Translational Research on Pancreatic Cancer registry

Al‐Batran

Hofheinz

Reichart

et al. 2020

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…A recent systematic review on PROs and PDAC identified only 170 studies employing PROMs in PDAC patients. 99 …”

Section: A Patient‐centered View Of Pancreatic Cancer Carementioning

confidence: 99%

“…Notably, the number of studies investigating PROs in advanced disease, especially beyond 12 months of disease is extremely limited, urging more investigation in this field, as the introduction of more effective intensified chemotherapy regimens is likely to guarantee a longer life expectancy for many patients. 99 …”

Section: A Patient‐centered View Of Pancreatic Cancer Carementioning

confidence: 99%

“…102 Notably, the number of studies investigating PROs in advanced disease, especially beyond 12 months of disease is extremely limited, urging more investigation in this field, as the introduction of more effective intensified chemotherapy regimens is likely to guarantee a longer life expectancy for many patients. 99 Over the past few years, there have been other attempts to develop specific sets of PROs with the collaboration of patients' representatives, but they have not been validated yet. 103,104 Another important aspect of patient-centered care is the need to engage the patient in the treatment process to obtain optimal compliance and better QoL and clinical results.…”

Section: A Patient-centered View Of Pancreatic Cancer Carementioning

confidence: 99%

See 1 more Smart Citation

UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better

et al. 2021

View full text Add to dashboard Cite

Background Pancreatic ductal adenocarcinoma is the deadliest cancer worldwide with a 98% loss‐of‐life expectancy and a 30% increase in the disability‐adjusted life years during the last decade in Europe. The disease cannot be effectively prevented nor being early detected. When diagnosed, 80% of patients have tumors that are in incurable stages, while for those who undergo surgery, 80% of patients will present with local or distant metastasis. Importantly, chemotherapies are far from being effective. Objective Pancreatic cancer represents a great challenge and, at the same time, a huge opportunity for advancing our understanding on the basis of the disease, the molecular profiles, that would lead to develop tools for early detection and effective treatments, thus, boosting patient survival. Results Research on pancreatic cancer has being receiving little or minimal funds from European funding bodies. UEG is calling for public‐private partnerships that would effectively fund research on pancreatic cancer. Conclusion This would increase our understanding of this disease and better treatment, through pan‐European efforts that take advantage of the strong academic European research landscape on pancreatic cancer, and the contribution by the industry of all sizes.

show abstract

“…With a 5-year survival rate of 9%, it is usually detected at advanced stages and has limited therapeutic options [2]. PDAC exhibits the characteristics of extensive desmoplasia, rapid metastasis, and advanced resistance to chemotherapy and radiation, rendering this disease a major priority for public health care [3]. One of the main reasons for such poor prognosis is the limited understanding of molecular mechanisms of PDAC progression.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma

Dai

Zhang

et al. 2020

Cancer Cell Int

View full text Add to dashboard Cite

Background: Pancreatic ductal adenocarcinoma (PDAC) is a lethal human malignancy, and previous researches support the contribution of microRNA (miRNA) to cancer progression. MiR-122-5p is reported to participate in the regulation of various cancers, while the function of miR-122-5p in PDAC remains unclear. In this study, we investigated the precise mechanism of miR-122-5p involved in PDAC pathogenesis. Methods: The expression levels of miR-122-5p were detected in human PDAC tissues and cell lines by miRNA RT-PCR. The effects of miR-122-5p on cell proliferation were explored by MTT assays, colony formation assays and flow cytometry assays. The ability of migration and invasion was determined by transwell assays. Dual Luciferase reporter assay was performed to validate the direct interaction between miR-122-5p and its target gene. The related molecules of cell cycle, apoptosis and epithelial-mesenchymal transition (EMT) were examined with qRT-PCR and western blot. In addition, xenograft mouse models were applied to explore the effects of miR-122-5p in vivo. Results: MiR-122-5p was underexpressed, while CCNG1 was highly expressed in PDAC tissues and cells. MiR-122-5p was negatively correlated with TNM stage, tumor size and lymph node metastasis in PDAC patients. Overexpression of miR-122-5p suppressed the proliferation, migration and invasion in vitro and inhibited tumorigenesis in vivo. Furthermore, CCNG1 was a direct target of miR-122-5p. Upregulated CCNG1 could partially reverse the effects caused by miR-122-5p. Moreover, miR-122-5p inhibited EMT through downregulation of CCNG1. Conclusion: Overexpression of miR-122-5p could inhibit cell proliferation, migration, invasion, and EMT by downregulating CCNG1 in PDAC, suggesting a potential therapeutic target for PDAC.

show abstract

Patient-reported outcome measures (PROMs) in pancreatic cancer: a systematic review

Cited by 29 publications

References 95 publications

UEG position paper on pancreatic cancer. Bringing pancreatic cancer to the 21st century: Prevent, detect, and treat the disease earlier and better

MicroRNA-122-5p inhibits cell proliferation, migration and invasion by targeting CCNG1 in pancreatic ductal adenocarcinoma

Contact Info

Product

Resources

About